AbbVie: The Inevitable Is Happening [Seeking Alpha]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Seeking Alpha
Humira's global sales fell 36% YoY, but AbbVie's other growth products performed well, leading to overall revenue growth after four consecutive down quarters. AbbVie's long-term growth prospects have improved due to the better-than-expected performance of several key products, the recent acquisition of ImmunoGen and the expected acquisition of Cerevel Therapeutics. In today's article, I analyze the recent developments and AbbVie's growth prospects and upside potential in the following years. Shares of AbbVie Inc. NYSE: ABBV ) closed nearly 5% lower after the first quarter earnings announcement last week, despite the company beating revenue and EPS expectations. Apparently, investors are worried about the erosion of Humira and the most Recommended For You Recommended For You About ABBV Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Global Uveitis Treatment Research Report 2024: Market to Reach $1.34 Billion by 2034, Fueled by Increased Prevalence, Treatment Improvements, and Strategic Alliances & Collaborations [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal [Yahoo! Finance]Yahoo! Finance
- In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit [Yahoo! Finance]Yahoo! Finance
- Euronext Paris Growth Leaders With High Insider Stakes May 2024 [Yahoo! Finance]Yahoo! Finance
- Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 5/8/24 - Form 8-K/A
- 5/7/24 - Form 4
- 5/7/24 - Form 4
- ABBV's page on the SEC website